Fujimoto Yukie, Ozawa Hiromi, Higuchi Tomoko, Miyagawa Yoshimasa, Bun Ayako, Imamura Michiko, Miyoshi Yasuo
Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Nishinomiya, Hyogo 663-8501, Japan.
Mol Clin Oncol. 2019 Feb;10(2):275-284. doi: 10.3892/mco.2018.1783. Epub 2018 Dec 4.
Although the neutrophil-to-lymphocyte ratio (NLR) is a valuable prognostic factor for early breast cancer, the patient subgroups that may benefit the most from NLR analysis remain unknown. The present study analyzed the prognostic significance of NLR according to absolute lymphocyte counts (ALCs). A total of 889 patients with operated early breast cancers were retrospectively recruited. Existing NLR and ALC baseline data from the time-period prior to operation or preoperative chemotherapy were collected. The cut-off value for NLR was set at 2.72 according to the receiver operating characteristic curve. Recurrence-free survival (RFS) of NLR-low patients at baseline (n=582) was significantly better than that of NLR-high patients (n=307, P=0.036). Improved patient prognoses were observed in the NLR-low, ALC-high (>1,688/µl; 5-year RFS, 0.88 vs. 0.57; P<0.0001) subgroup (n=355), but not in the NLR-low, ALC-low (≤1,688/µl; 5-year RFS, 0.87 vs. 0.87; P=0.46) subgroup (n=534). Using multivariate analysis, NLR was observed to be a significant and independent factor for RFS (hazard ratio: 3.52; 95% confidence interval: 1.61-7.32; P=0.0023) in the ALC-high breast cancer subgroup. Prognostic significance for baseline NLR was found exclusively in the ALC - high subgroup. Since NLR is a simple marker, the results obtained here might be useful for identifying patients who have high recurrence risk, and those that are candidates for additional treatments.
尽管中性粒细胞与淋巴细胞比值(NLR)是早期乳腺癌的一个有价值的预后因素,但可能从NLR分析中获益最大的患者亚组仍不明确。本研究根据绝对淋巴细胞计数(ALC)分析了NLR的预后意义。共回顾性纳入了889例接受手术治疗的早期乳腺癌患者。收集了手术前或术前化疗前时间段的现有NLR和ALC基线数据。根据受试者工作特征曲线,将NLR的临界值设定为2.72。基线时NLR低的患者(n = 582)的无复发生存期(RFS)显著优于NLR高的患者(n = 307,P = 0.036)。在NLR低、ALC高(>1,688/µl;5年RFS,0.88对0.57;P<0.0001)亚组(n = 355)中观察到患者预后改善,但在NLR低、ALC低(≤1,688/µl;5年RFS,0.87对0.87;P = 0.46)亚组(n = 534)中未观察到。使用多因素分析,在ALC高的乳腺癌亚组中,NLR被观察到是RFS的一个显著且独立的因素(风险比:3.52;95%置信区间:1.61 - 7.32;P = 0.0023)。仅在ALC高的亚组中发现基线NLR具有预后意义。由于NLR是一个简单的标志物,此处获得的结果可能有助于识别具有高复发风险的患者以及那些适合额外治疗的患者。